ERCC2 validated as chemotherapy response biomarker in bladder cancer
Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma.
Source: MedWire News - Category: Consumer Health News Tags: Oncology Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Genetics | Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy